Michael Wacker

Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-Catch™ technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs.